Kymera Therapeutics(KYMR) - 2025 Q4 - Annual Results

Financial Position - Kymera Therapeutics has $1.6 billion in cash, providing a runway into 2029[1] Clinical Trials - The KT-621 BROADEN2 Phase 2b trial in atopic dermatitis (AD) is ongoing, with data expected by mid-2027, and the trial includes approximately 200 patients[6] - The KT-621 BREADTH Phase 2b trial in asthma has been initiated, with data expected in late-2027, involving approximately 264 adult patients[6] - KT-621 received FDA Fast Track designation for the treatment of moderate to severe AD in December 2025[6] - In December 2025, KT-621 demonstrated significant reductions in Type 2 inflammatory biomarkers and improvements in clinical endpoints in a Phase 1b trial[6] - The primary endpoint for the BROADEN2 trial is the percent change from baseline in Eczema Area and Severity Index (EASI) score at week 16[6] - The primary endpoint for the BREADTH trial is the percent change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)[6] Development Pipeline - The company plans to advance at least one new development candidate towards IND for a first-in-class oral immunology program in 2026[10] - KT-579, an investigational oral degrader, is expected to initiate its first-in-human Phase 1 trial in Q1 2026, with data anticipated in the second half of 2026[9] Strategic Vision - Kymera aims to reshape the treatment of common immuno-inflammatory diseases with its innovative oral therapies[2]